Literature DB >> 18393970

Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats.

Michelle Roche1, John P Kelly, Maeve O'Driscoll, David P Finn.   

Abstract

The endogenous cannabinoid system plays an important role in regulating the immune system. Modulation of endogenous cannabinoids represents an attractive alternative for the treatment of inflammatory disorders. This study investigated the effects of URB597, a selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme catalysing degradation of the endogenous cannabinoid anandamide, and AM404, an inhibitor of anandamide transport, on lipopolysaccharide (LPS)-induced increases in plasma cytokine levels in rats. Both URB597 and AM404 potentiated the LPS-induced increase in plasma tumour necrosis factor-alpha (TNF-alpha) levels. The peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, GW9662, attenuated the AM404-induced augmentation of TNF-alpha levels. Furthermore, the selective cannabinoid CB1 and CB2 receptor antagonists, AM251 and AM630 respectively, and the transient receptor potential vanilloid receptor-1 (TRPV1) antagonist, SB366791, reduced LPS-induced TNF-alpha plasma levels both alone and in combination with AM404. In contrast, AM404 inhibited LPS-induced increases in circulating interleukin-1beta (IL-1beta) and IL-6. AM251 attenuated the immunosuppressive effect of AM404 on IL-1beta. None of the antagonists altered the effect of AM404 on LPS-induced IL-6. Moreover, AM251, AM630 and SB366791, administered alone, inhibited LPS-induced increases in plasma IL-1beta and IL-6 levels. In conclusion, inhibition of endocannabinoid degradation or transport in vivo potentiates LPS-induced increases in circulating TNF-alpha levels, an effect which may be mediated by PPARgamma and is also reduced by pharmacological blockade of CB1, CB2 and TRPV1. The immunosuppressive effect of AM404 on IL-1beta levels is mediated by the cannabinoid CB1 receptor. Improved understanding of endocannabinoid-mediated regulation of immune function has fundamental physiological and potential therapeutic significance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393970      PMCID: PMC2561133          DOI: 10.1111/j.1365-2567.2008.02838.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  53 in total

1.  Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells.

Authors:  E V Berdyshev; E Boichot; N Germain; N Allain; J P Anger; V Lagente
Journal:  Eur J Pharmacol       Date:  1997-07-09       Impact factor: 4.432

2.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides.

Authors:  B F Cravatt; D K Giang; S P Mayfield; D L Boger; R A Lerner; N B Gilula
Journal:  Nature       Date:  1996-11-07       Impact factor: 49.962

3.  The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway.

Authors:  F Molina-Holgado; E Molina-Holgado; C Guaza
Journal:  FEBS Lett       Date:  1998-08-14       Impact factor: 4.124

Review 4.  Endocannabinoids.

Authors:  R Mechoulam; E Fride; V Di Marzo
Journal:  Eur J Pharmacol       Date:  1998-10-16       Impact factor: 4.432

5.  Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Exp Neurol       Date:  2006-10-11       Impact factor: 5.330

6.  Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion.

Authors:  C J Hillard; W S Edgemond; A Jarrahian; W B Campbell
Journal:  J Neurochem       Date:  1997-08       Impact factor: 5.372

7.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide.

Authors:  P M Zygmunt; J Petersson; D A Andersson; H Chuang; M Sørgård; V Di Marzo; D Julius; E D Högestätt
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

8.  Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid.

Authors:  R Gallily; A Yamin; Y Waksmann; H Ovadia; J Weidenfeld; A Bar-Joseph; A Biegon; R Mechoulam; E Shohami
Journal:  J Pharmacol Exp Ther       Date:  1997-11       Impact factor: 4.030

9.  Functional role of high-affinity anandamide transport, as revealed by selective inhibition.

Authors:  M Beltramo; N Stella; A Calignano; S Y Lin; A Makriyannis; D Piomelli
Journal:  Science       Date:  1997-08-22       Impact factor: 47.728

10.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

View more
  17 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Contributions of TRPV1, endovanilloids, and endoplasmic reticulum stress in lung cell death in vitro and lung injury.

Authors:  Karen C Thomas; Jessica K Roberts; Cassandra E Deering-Rice; Erin G Romero; Randal O Dull; Jeewoo Lee; Garold S Yost; Christopher A Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-23       Impact factor: 5.464

3.  The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors.

Authors:  Alexandre A Steiner; Alla Y Molchanova; M Devrim Dogan; Shreya Patel; Erika Pétervári; Márta Balaskó; Samuel P Wanner; Justin Eales; Daniela L Oliveira; Narender R Gavva; M Camila Almeida; Miklós Székely; Andrej A Romanovsky
Journal:  J Physiol       Date:  2011-03-14       Impact factor: 5.182

Review 4.  Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.

Authors:  Matthew N Hill; Patrizia Campolongo; Rachel Yehuda; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2017-07-26       Impact factor: 7.853

5.  Hemorphins act as homeostatic agents in response to endotoxin-induced stress.

Authors:  Nina Barkhudaryan; Hermine Zakaryan; Flora Sarukhanyan; Anna Gabrielyan; Dominik Dosch; Josef Kellermann; Friedrich Lottspeich
Journal:  Neurochem Res       Date:  2009-12-05       Impact factor: 3.996

6.  Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain.

Authors:  Matthew S Alkaitis; Carlos Solorzano; Russell P Landry; Daniele Piomelli; Joyce A DeLeo; E Alfonso Romero-Sandoval
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

7.  The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action.

Authors:  D M Kerr; B Harhen; B N Okine; L J Egan; D P Finn; M Roche
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

8.  Cnr2 deficiency confers resistance to inflammation-induced preterm birth in mice.

Authors:  Xiaofei Sun; Monica Cappelletti; Yingju Li; Christopher L Karp; Senad Divanovic; Sudhansu K Dey
Journal:  Endocrinology       Date:  2014-07-22       Impact factor: 4.736

9.  Effects of the monoacylglycerol lipase inhibitor JZL184 on chickens infected with avian pathogenic Escherichia coli O78: A preliminary pharmacokinetic and infection study.

Authors:  Cherry P Ho; Abdolsamad Borazjani; Matthew K Ross; Chinling Wang
Journal:  Can J Vet Res       Date:  2020-07       Impact factor: 1.310

10.  Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis.

Authors:  J T Toguri; C Lehmann; R B Laprairie; A M Szczesniak; J Zhou; E M Denovan-Wright; M E M Kelly
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.